Update (June 16, 2026): Grapiprant Plus Tapentadol Extends Postoperative Analgesia to 3 Hours in Cats Undergoing Ovariohysterectomy

TL;DR. A randomized feline trial found that combining grapiprant with the opioid tapentadol extended postoperative analgesia after ovariohysterectomy beyond either drug alone, without compromising intraoperative stability.

What just dropped

• Randomized, prospective, blinded trial in 60 cats undergoing elective ovariohysterectomy (https://europepmc.org/articles/PMC12852605): the grapiprant-tapentadol combination provided postoperative analgesia lasting up to 3 hours, longer than the roughly 2 hours seen with grapiprant or tapentadol alone.
• No adverse effects or statistically significant differences in intraoperative physiological parameters were observed between groups; the combination delayed the need for rescue analgesia.
• A 2026 veterinary osteoarthritis treatment review (https://europepmc.org/articles/PMC13162164) places EP4 (prostaglandin E2 receptor) blockers like grapiprant among the modern options for animal OA pain.

Context

Grapiprant (Galliprant) is a piprant-class EP4 prostaglandin-receptor antagonist licensed for canine osteoarthritis pain. Its use in cats is off-label, and controlled feline data have been limited, so the Alegre 2026 trial is a useful addition. Cats were randomized to placebo, grapiprant alone, tapentadol alone, or the grapiprant-tapentadol combination, dosed orally before surgery; postoperative pain was scored with two validated feline scales (the UNESP-Botucatu short form and the Feline Grimace Scale), which showed strong inter-rater reliability.

The combination group reached statistically significant differences from control on grimace scoring at 3 hours and required rescue analgesia later than control or grapiprant-alone groups. The Quintao 2026 review situates this within the broader move toward mechanism-based, often multimodal OA and pain management across companion-animal species, in which EP4 blockade is one validated target alongside COX inhibitors and biologicals.

What this changes in grapiprant (Galliprant) for canine osteoarthritis pain (https://www.thevoyage.ai/forvets/knowledge/grapiprant-canine-osteoarthritis-pain)

This is feline, perioperative, off-label data, so it does not extend the canine OA label or establish a feline dose, which remains a formulary and clinical-judgment decision. But it adds controlled evidence that grapiprant can contribute to multimodal analgesia and pairs logically with an opioid for acute surgical pain, broadening the clinical context captured by the evergreen.

Voyage Clinical Desk

From clinical question to SOAP draft -- cited differentials, live dose calculators, owner handouts. Trained on the veterinary canon (Plumb's, Ettinger, JVIM, ACVIM consensus, 50,000+ indexed references). First answer free, no signup.

Open Voyage Clinical Desk: https://www.thevoyage.ai/forvets/ask?context=update-2026-06-16-grapiprant-feline-multimodal-analgesia

References

1. Alegre EA, Lima BJ, Vieira B, et al. Efficacy of combined grapiprant and tapentadol for analgesia in cats undergoing elective ovariohysterectomy. J Feline Med Surg. 2026;28(1). https://europepmc.org/articles/PMC12852605
2. Quintao NLM, Moffa EB, Kroier M, et al. Overview of the Current Osteoarthritis Treatment in Veterinary Medicine and Future Directions. ACS Pharmacol Transl Sci. 2026;9(5):1037-1054. https://europepmc.org/articles/PMC13162164

Related reads

• Grapiprant (Galliprant) for Canine Osteoarthritis Pain: EP4 Antagonism and Clinical Evidence
• Robenacoxib (Onsior) for Pain in Cats and Dogs: COX-2 Selectivity and Clinical Evidence